26 February 2026
Johnson & Johnson Reports Positive Early Results for Pasritamig and Docetaxel in Prostate Cancer
Phase 1b study shows pasritamig and docetaxel combo is safe and effective in prostate cancer, with high PSA response rates, supporting Phase 3 trials.
